Pontifax (Israel) IV, L.P.
CIK 0001726039 Name as filed on the most recent filing
Filed as Pontifax (Israel) IV, L.P. (9)
37 transaction lines · from 9 filings · filed 2018-03-23 to 2025-10-17 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
0 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2025-10-15 |
Keros Therapeutics, Inc. KROS |
S, Open-market sale | 2,284,612 disposed | 17.75 | 40,551,863.00 | Form 4, filing 0000921895-25-002765 | |
| 2025-10-15 |
Keros Therapeutics, Inc. KROS |
S, Open-market sale | 1,226,412 disposed | 17.75 | 21,768,813.00 | Form 4, filing 0000921895-25-002765 | |
| 2025-10-15 |
Keros Therapeutics, Inc. KROS |
S, Open-market sale | 1,121,045 disposed | 17.75 | 19,898,548.75 | Form 4, filing 0000921895-25-002765 | |
| 2025-10-15 |
Keros Therapeutics, Inc. KROS |
S, Open-market sale | 155,262 disposed | 17.75 | 2,755,900.50 | Form 4, filing 0000921895-25-002765 | |
| 2021-05-13 |
Eloxx Pharmaceuticals, Inc. ELOX |
P, Open-market purchase | 2,630,487 acquired | 1.35 | 3,551,157.45 | Form 4, filing 0001104659-21-067336 | |
| 2021-05-13 |
Eloxx Pharmaceuticals, Inc. ELOX |
P, Open-market purchase | 1,422,222 acquired | 1.35 | 1,919,999.70 | Form 4, filing 0001104659-21-067336 | |
| 2021-05-13 |
Eloxx Pharmaceuticals, Inc. ELOX |
P, Open-market purchase | 1,280,624 acquired | 1.35 | 1,728,842.40 | Form 4, filing 0001104659-21-067336 | |
| 2021-05-13 |
Eloxx Pharmaceuticals, Inc. ELOX |
P, Open-market purchase | 592,592 acquired | 1.35 | 799,999.20 | Form 4, filing 0001104659-21-067336 | |
| 2020-11-17 |
Keros Therapeutics, Inc. KROS |
P, Open-market purchase | 26,634 acquired | 50.00 | 1,331,700.00 | Form 4, filing 0001209191-20-059410 | |
| 2020-11-17 |
Keros Therapeutics, Inc. KROS |
P, Open-market purchase | 14,400 acquired | 50.00 | 720,000.00 | Form 4, filing 0001209191-20-059410 | |
| 2020-11-17 |
Keros Therapeutics, Inc. KROS |
P, Open-market purchase | 12,966 acquired | 50.00 | 648,300.00 | Form 4, filing 0001209191-20-059410 | |
| 2020-11-17 |
Keros Therapeutics, Inc. KROS |
P, Open-market purchase | 6,000 acquired | 50.00 | 300,000.00 | Form 4, filing 0001209191-20-059410 | |
| 2020-11-17 |
Keros Therapeutics, Inc. KROS |
P, Open-market purchase | 26,634 acquired | 50.00 | 1,331,700.00 | Form 4, filing 0001209191-20-059411 | |
| 2020-11-17 |
Keros Therapeutics, Inc. KROS |
P, Open-market purchase | 14,400 acquired | 50.00 | 720,000.00 | Form 4, filing 0001209191-20-059411 | |
| 2020-11-17 |
Keros Therapeutics, Inc. KROS |
P, Open-market purchase | 12,966 acquired | 50.00 | 648,300.00 | Form 4, filing 0001209191-20-059411 | |
| 2020-11-17 |
Keros Therapeutics, Inc. KROS |
P, Open-market purchase | 6,000 acquired | 50.00 | 300,000.00 | Form 4, filing 0001209191-20-059411 | |
| 2020-11-17 |
Keros Therapeutics, Inc. KROS |
P, Open-market purchase | 26,634 acquired | 50.00 | 1,331,700.00 | Form 4, filing 0001209191-20-059404 | |
| 2020-11-17 |
Keros Therapeutics, Inc. KROS |
P, Open-market purchase | 14,400 acquired | 50.00 | 720,000.00 | Form 4, filing 0001209191-20-059404 | |
| 2020-11-17 |
Keros Therapeutics, Inc. KROS |
P, Open-market purchase | 12,966 acquired | 50.00 | 648,300.00 | Form 4, filing 0001209191-20-059404 | |
| 2020-11-17 |
Keros Therapeutics, Inc. KROS |
P, Open-market purchase | 6,000 acquired | 50.00 | 300,000.00 | Form 4, filing 0001209191-20-059404 | |
| 2020-04-13 |
Keros Therapeutics, Inc. KROS |
P, Open-market purchase | 194,203 acquired | 16.00 | 3,107,248.00 | Form 4, filing 0001209191-20-024231 | |
| 2020-04-13 |
Keros Therapeutics, Inc. KROS |
P, Open-market purchase | 105,000 acquired | 16.00 | 1,680,000.00 | Form 4, filing 0001209191-20-024231 | |
| 2020-04-13 |
Keros Therapeutics, Inc. KROS |
P, Open-market purchase | 94,546 acquired | 16.00 | 1,512,736.00 | Form 4, filing 0001209191-20-024231 | |
| 2020-04-13 |
Keros Therapeutics, Inc. KROS |
P, Open-market purchase | 43,750 acquired | 16.00 | 700,000.00 | Form 4, filing 0001209191-20-024231 | |
| 2019-06-24 |
Eloxx Pharmaceuticals, Inc. ELOX |
P, Open-market purchase | 86,806 acquired | 9.00 | 781,254.00 | Form 4, filing 0001144204-19-032482 | |
| 2019-06-24 |
Eloxx Pharmaceuticals, Inc. ELOX |
P, Open-market purchase | 46,933 acquired | 9.00 | 422,397.00 | Form 4, filing 0001144204-19-032482 | |
| 2019-06-24 |
Eloxx Pharmaceuticals, Inc. ELOX |
P, Open-market purchase | 42,261 acquired | 9.00 | 380,349.00 | Form 4, filing 0001144204-19-032482 | |
| 2019-06-24 |
Eloxx Pharmaceuticals, Inc. ELOX |
P, Open-market purchase | 24,000 acquired | 9.00 | 216,000.00 | Form 4, filing 0001144204-19-032482 | |
| 2018-04-30 |
Eloxx Pharmaceuticals, Inc. ELOX |
P, Open-market purchase | 172,626 acquired | 9.75 | 1,683,103.50 | Form 4, filing 0001209191-18-027114 | |
| 2018-04-30 |
Eloxx Pharmaceuticals, Inc. ELOX |
P, Open-market purchase | 93,333 acquired | 9.75 | 909,996.75 | Form 4, filing 0001209191-18-027114 | |
| 2018-04-30 |
Eloxx Pharmaceuticals, Inc. ELOX |
P, Open-market purchase | 84,041 acquired | 9.75 | 819,399.75 | Form 4, filing 0001209191-18-027114 | |
| 2018-03-22 |
Eloxx Pharmaceuticals, Inc. ELOX |
P, Open-market purchase | 2,959 acquired | 8.00 | 23,672.00 | Form 4, filing 0001209191-18-021389 | |
| 2018-03-22 |
Eloxx Pharmaceuticals, Inc. ELOX |
P, Open-market purchase | 1,600 acquired | 8.00 | 12,800.00 | Form 4, filing 0001209191-18-021389 | |
| 2018-03-22 |
Eloxx Pharmaceuticals, Inc. ELOX |
P, Open-market purchase | 1,441 acquired | 8.00 | 11,528.00 | Form 4, filing 0001209191-18-021389 | |
| 2018-03-21 |
Eloxx Pharmaceuticals, Inc. ELOX |
P, Open-market purchase | 3,255 acquired | 7.55 | 24,575.25 | Form 4, filing 0001209191-18-021389 | |
| 2018-03-21 |
Eloxx Pharmaceuticals, Inc. ELOX |
P, Open-market purchase | 1,760 acquired | 7.55 | 13,288.00 | Form 4, filing 0001209191-18-021389 | |
| 2018-03-21 |
Eloxx Pharmaceuticals, Inc. ELOX |
P, Open-market purchase | 1,585 acquired | 7.55 | 11,966.75 | Form 4, filing 0001209191-18-021389 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- S, Open-market sale
- Open-market sale
- P, Open-market purchase
- Open-market purchase
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.
How to cite this page
ebomi catalog. Pontifax (Israel) IV, L.P., insider transactions. Retrieved 2026-08-20 from https://ebomi.com/insider/0001726039
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6